Browse by Person

View wider browse menu Up a level
[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 4.

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2019) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 30 (2). p. 344. ISSN 0923-7534

Schöffski, P, Wozniak, A, Kasper, B et al. (23 more authors) (2018) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of Oncology, 29 (3). pp. 758-765. ISSN 0923-7534

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534

Rapley, EA, Hockley, S, Warren, W et al. (36 more authors) (2004) Somatic mutations of KIT in familial testicular germ cell tumours. British Journal of Cancer, 90 (12). 2397 - 2401. ISSN 0007-0920

This list was generated on Sun Sep 13 02:16:14 2020 BST.